Finding new adjuvants is an integrated component of the efforts in developing an effective HIV-1 vaccine. Compared\nwith traditional adjuvants, a modern adjuvant in the context of HIV-1 prevention would elicit a durable and potent\nmemory response from B cells, CD8+ T cells, and NK cells but avoid overstimulation of HIV-1 susceptible CD4+ T cells,\nespecially at genital and rectal mucosa, the main portals for HIV-1 transmission. We briefly review recent advances in\nthe studies of such potential targeted adjuvants, focusing on three classes of molecules that we study: TNFSF molecules,\nTLRs agonists, and NODs agonists
Loading....